Akero Therapeutics, Inc. Breach of Fiduciary Duties Investigation

Contact UsFree Case Evaluation

"*" indicates required fields

First Name*

Last Name*

Email Address*

Phone Number*

Practice Area

City*

State*

Please describe your potential case or matter.**

By clicking SUBMIT you agree to our Terms of Use and Privacy Policy and you are providing express consent to receive communications from Berger Montague via calls, emails, and/or text messages.

Practice Area: Securities Fraud & Investor Protection

Case Status: Pending

Ticker Symbol: NASDAQ: AKRO

Berger Montague is investigating Akero Therapeutics and its board of directors for potential breaches of fiduciary duties and violations of the federal securities laws.

Headquartered in San Francisco, Akero is a clinical stage biopharmaceutical company whose lead product candidate is efruxifermin (EFX), a drug in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH).

Berger Montague’s investigation centers on a proposed merger with Novo Nordisk A/S, announced on October 9, 2025, whereby Akero shareholders will receive $54.00 per share in cash and one Contingent Value Right entitling each holder to receive $6.00 per share if Akero’s lead product candidate efruxifermin, a drug in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), achieves regulatory approval by June 30, 2031.

Shareholders of Akero may learn more about this investigation by contacting Berger Montague: Andrew Abramowitz at aabramowitz@bergermontague.com or (215) 875-3015 or Radha Raghavan at rraghavan@bergermontague.com or (215) 875-4698.